Front Matter
Pages i-xiii

Genomic Complexity of Osteosarcoma and Its Implication for Preclinical and Clinical Targeted Therapies
Courtney Schott, Avanthi Tayi Shah, E. Alejandro Sweet-Cordero
Pages 1-19
Genomics and the Immune Landscape of Osteosarcoma
Chia-Chin Wu, J. Andrew Livingston
Pages 21-36
RECQ DNA Helicases and Osteosarcoma
Linchao Lu, Weidong Jin, Lisa L. Wang
Pages 37-54
Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma
Christopher D. Collier, Patrick J. Getty, Edward M. Greenfield
Pages 55-75
Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma
Mary Frances Wedekind, Timothy P. Cripe
Pages 77-89
Applying Osteosarcoma Immunology to Understand Disease Progression and Assess Immunotherapeutic Response
Hillary G. Pratt, E. Markel Justin, Brock A. Lindsey
Pages 91-109
Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma
James Brandon Reinecke, Ryan David Roberts
Pages 111-123
Wnt Signaling in Osteosarcoma
Amit Singla, Jichuan Wang, Rui Yang, David S. Geller, David M. Loeb, Bang H. Hoang
Pages 125-139
Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update
Edward M. Greenfield, Christopher D. Collier, Patrick J. Getty
Pages 141-155
The Role of ALDH in the Metastatic Potential of Osteosarcoma Cells and Potential ALDH Targets
Rebekah Belayneh, Kurt Weiss
Pages 157-166
Autophagy in Osteosarcoma
Grace Nehme, Nancy Gordon
Pages 167-175
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases
Nadya Koshkina, Yuanzheng Yang, Eugenie S. Kleinerman
Pages 177-187
Exosomes: Dynamic Mediators of Extracellular Communication in the Tumor Microenvironment
Kerri Wolf-Dennen, Eugenie S. Kleinerman
Pages 189-197
Comparative Immunology and Immunotherapy of Canine Osteosarcoma
Nicola J. Mason
Pages 199-221
Back Matter
Pages 223-233

This thoroughly revised second edition is an up-to-date overview of the new advances in the knowledge of the basic science in sarcoma and osteosarcoma. It features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, this essential volume also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists.